Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clover Leaf
New Haven, Connecticut, United Statescloverleafbio.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Cloverleaf Bio is developing engineered tRNA therapeutics for oncology with a platform capable of directly inhibiting up to 25 cancer-associated enzymes per molecule. As of October 2025, all evidence indicates pre-clinical development and no clinical trial results published[1][3][4].
- Therapeutic areas
- Oncology
- Modalities
- RNA therapyEngineered tRNA therapeutic
- Industry
- Biotech
02
Partnerships
Mission BioCapital (seed funding and acceleration support)[3]
Beyond the preview
Go deeper on Clover Leaf.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clover Leaf.